MOBILE-HEALTH NETWORK SOLUTI (MNDR) Fundamental Analysis & Valuation

NASDAQ:MNDR • KYG622641259

0.8631 USD
+0 (+0.36%)
At close: Mar 13, 2026
0.8458 USD
-0.02 (-2%)
After Hours: 3/13/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MNDR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to MNDR. MNDR was compared to 101 industry peers in the Health Care Providers & Services industry. The financial health of MNDR is average, but there are quite some concerns on its profitability. MNDR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. MNDR Profitability Analysis

1.1 Basic Checks

  • In the past year MNDR has reported negative net income.
  • In the past year MNDR has reported a negative cash flow from operations.
  • In the past 5 years MNDR reported 4 times negative net income.
  • MNDR had negative operating cash flow in 4 of the past 5 years.
MNDR Yearly Net Income VS EBIT VS OCF VS FCFMNDR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2025 0 -5M -10M -15M

1.2 Ratios

  • MNDR has a worse Return On Assets (-113.31%) than 94.06% of its industry peers.
  • The Return On Equity of MNDR (-192.59%) is worse than 78.22% of its industry peers.
Industry RankSector Rank
ROA -113.31%
ROE -192.59%
ROIC N/A
ROA(3y)-121.89%
ROA(5y)-86.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MNDR Yearly ROA, ROE, ROICMNDR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2025 0 200 -200 400 600 800

1.3 Margins

  • With a Gross Margin value of 16.06%, MNDR is not doing good in the industry: 62.38% of the companies in the same industry are doing better.
  • In the last couple of years the Gross Margin of MNDR has declined.
  • The Profit Margin and Operating Margin are not available for MNDR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 16.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.44%
GM growth 5YN/A
MNDR Yearly Profit, Operating, Gross MarginsMNDR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 2025 0 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. MNDR Health Analysis

2.1 Basic Checks

  • MNDR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MNDR has been reduced compared to 1 year ago.
  • There is no outstanding debt for MNDR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MNDR Yearly Shares OutstandingMNDR Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 5M 10M
MNDR Yearly Total Debt VS Total AssetsMNDR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

2.2 Solvency

  • Based on the Altman-Z score of -9.56, we must say that MNDR is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of MNDR (-9.56) is worse than 89.11% of its industry peers.
  • There is no outstanding debt for MNDR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.56
ROIC/WACCN/A
WACC8.91%
MNDR Yearly LT Debt VS Equity VS FCFMNDR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 0 5M -5M

2.3 Liquidity

  • A Current Ratio of 1.06 indicates that MNDR should not have too much problems paying its short term obligations.
  • MNDR has a worse Current ratio (1.06) than 62.38% of its industry peers.
  • MNDR has a Quick Ratio of 1.06. This is a bad value and indicates that MNDR is not financially healthy enough and could expect problems in meeting its short term obligations.
  • MNDR has a Quick ratio of 0.99. This is in the lower half of the industry: MNDR underperforms 62.38% of its industry peers.
Industry RankSector Rank
Current Ratio 1.06
Quick Ratio 0.99
MNDR Yearly Current Assets VS Current LiabilitesMNDR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MNDR Growth Analysis

3.1 Past

  • MNDR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -303.19%.
  • MNDR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -42.16%.
  • MNDR shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.04% yearly.
EPS 1Y (TTM)-303.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-325.52%
Revenue 1Y (TTM)-42.16%
Revenue growth 3Y3.04%
Revenue growth 5YN/A
Sales Q2Q%-45.26%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y150%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year76.44%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MNDR Yearly Revenue VS EstimatesMNDR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 10B 20B 30B 40B
MNDR Yearly EPS VS EstimatesMNDR Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0 -1 -2 -3 -4 -5

More info and screens

Find the best growth stocksShow best growing peers

1

4. MNDR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MNDR. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 42.31, the valuation of MNDR can be described as expensive.
  • MNDR's Price/Forward Earnings ratio is in line with the industry average.
  • The average S&P500 Price/Forward Earnings ratio is at 23.84. MNDR is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 42.31
MNDR Price Earnings VS Forward Price EarningsMNDR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNDR Per share dataMNDR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15

4.3 Compensation for Growth

  • MNDR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MNDR Dividend Analysis

5.1 Amount

  • No dividends for MNDR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MNDR Fundamentals: All Metrics, Ratios and Statistics

MOBILE-HEALTH NETWORK SOLUTI

NASDAQ:MNDR (3/13/2026, 8:00:02 PM)

After market: 0.8458 -0.02 (-2%)

0.8631

+0 (+0.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)10-23
Earnings (Next)N/A
Inst Owners3.82%
Inst Owner Change346.23%
Ins Owners8.48%
Ins Owner ChangeN/A
Market Cap1.58M
Revenue(TTM)11.92M
Net Income(TTM)-5.04M
Analysts82.86
Price TargetN/A
Short Float %0.77%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 42.31
P/S 0.13
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB 6.17
EV/EBITDA N/A
EPS(TTM)-19.48
EYN/A
EPS(NY)0.02
Fwd EY2.36%
FCF(TTM)-3.71
FCFYN/A
OCF(TTM)-2.38
OCFYN/A
SpS6.52
BVpS1.43
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -113.31%
ROE -192.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 16.06%
FCFM N/A
ROA(3y)-121.89%
ROA(5y)-86.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.44%
GM growth 5YN/A
F-Score4
Asset Turnover2.68
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1416.51%
Cap/Sales 20.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.06
Quick Ratio 0.99
Altman-Z -9.56
F-Score4
WACC8.91%
ROIC/WACCN/A
Cap/Depr(3y)567.57%
Cap/Depr(5y)346.48%
Cap/Sales(3y)11.73%
Cap/Sales(5y)7.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-303.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-325.52%
EPS Next Y150%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-42.16%
Revenue growth 3Y3.04%
Revenue growth 5YN/A
Sales Q2Q%-45.26%
Revenue Next Year76.44%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y69.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year161.12%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.94%
OCF growth 3YN/A
OCF growth 5YN/A

MOBILE-HEALTH NETWORK SOLUTI / MNDR FAQ

What is the ChartMill fundamental rating of MOBILE-HEALTH NETWORK SOLUTI (MNDR) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MNDR.


What is the valuation status for MNDR stock?

ChartMill assigns a valuation rating of 1 / 10 to MOBILE-HEALTH NETWORK SOLUTI (MNDR). This can be considered as Overvalued.


How profitable is MOBILE-HEALTH NETWORK SOLUTI (MNDR) stock?

MOBILE-HEALTH NETWORK SOLUTI (MNDR) has a profitability rating of 0 / 10.


How financially healthy is MOBILE-HEALTH NETWORK SOLUTI?

The financial health rating of MOBILE-HEALTH NETWORK SOLUTI (MNDR) is 5 / 10.